ARCHIVES

John Durant Names ASCO Executive NP; A New Position, New Voice In Washington

This article is from The Cancer Letter archive.

Vol. 20 No. 46 | December 2, 1994

Download PDF Visit The Full Archive

Related Articles

BRAF Inhibitor Shrank Tumors In Phase II Genentech Study

November 26, 2010

Broder; Cancer Act’s Special Authorities Don’t Give Director Immunity For NIH, HHS

September 27, 1991

In Brief: William Longmire Replaces Fisher On Cancer Panel; Talbot Urges Organizations To Avoid Polarization

July 9, 1982

Genetronics Phase II Trials For Head & Neck Completed.

May 4, 2001

PRI Drops Suit Against Top Two FCRF Staff; Gilden, Compton Accept “Partnership” Offers

August 22, 1986

SWOG Restarts Gynecologic Malignancies Committee.

May 16, 2008